Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant

Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant

Direct-acting oral anticoagulants (DOACs) represent the standard for preventing stroke and systemic embolization (SSE) in patients with atrial fibrillation (AF). There is limited information for patients ≥ 80 years. We report a retrospective analysis of AF patients ≥ 80 years prescribed either a US...

Full description

Bibliographic Details
Main Authors: Roy Taoutel, Michael D. Ezekowitz, Usman A. Chaudhry, Carly Weber, Dana Hassan, Ed J. Gracely, Mohammed H. Kamareddine, Benjamin I. Horn, Glenn R. Harper
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:International Journal of Cardiology: Heart & Vasculature
Subjects:
Atrial fibrillation
Direct-acting oral anticoagulants
DOAC
Elderly
Online Access:http://www.sciencedirect.com/science/article/pii/S2352906722001798

Internet

http://www.sciencedirect.com/science/article/pii/S2352906722001798

Similar Items